Articles related to METABOLIC HEALTH

Bariatric surgery volumes peaked in 2022 and have fallen since, with sleeve gastrectomy losing ground and Roux-en-Y conversions climbing as GLP-1 prescriptions expand.

A systematic review of 27 studies found behavioral sleep interventions — particularly CBT-I and sleep hygiene — reduced BMI and body weight in adults with poor sleep health, with the largest effects among patients with obesity.

Retrospective analyses presented at SABCS 2025 associated GLP-1 receptor agonist use with weight loss, mortality, and recurrence signals in breast cancer cohorts, with effects on endocrine therapy tolerability also observed.

Boehringer Ingelheim’s SYNCHRONIZE-1 phase 3 trial reported 16.6% average body weight reduction with survodutide, a dual GLP-1/glucagon receptor agonist, over 76 weeks in adults without type 2 diabetes.

Rodent and non-human primate studies showed glucagon and GIP agonism alone produced weight loss comparable to GLP-1-containing triple agonists in a Bluewater Biosciences-funded program.

Children labeled metabolically healthy at obesity treatment initiation reached an 18-fold higher type 2 diabetes incidence by age 30 than general population peers in a 42,911-patient Swedish cohort.